Ethiopia: GMP compliant local drug and API sector would yield health and economic benefits

By Gareth Macdonald contact

- Last updated on GMT

Ethiopia aims to make first API by 2020
Ethiopia aims to make first API by 2020

Related tags: Active ingredient

Ethiopia will start making its own APIs in 2020 according to the Government which says local manufacture will improve access to medicines, curb sale of counterfeits and promote innovation.

The Ethiopian Government published its Pharmaceutical Manufacturing Sector Strategy and Action Plan​ (2015 -2025) yesterday, explaining that the aim is to make the country’s drug manufacturing sector fully good manufacturing practices (GMP) compliant by 2025.

This will require a considerable effort as – according to the report – currently only two Ethiopian companies are GMP-compliant, although two more are about to acquire GMP certificates from the PIC/S.

But, despite the challenge, the rationale for improving standards is clear according to Prof Tsige Gebre-Mariam from Addis Ababa University’s School of Pharmacy.

There are major public health and economic benefits to be derived from local production of essential medicines and a thriving domestic pharmaceutical industry​” Gebre-Mariam told us.

He cited improved access to medicines, enhanced protection against counterfeits and reduced reliance on imports among the benefits of local production, explaining that at present only 20% of medicines used in the country are produced locally.

Ethiopia aspires to be self-reliant in essential medicines and this can be achieved by developing a viable and value-added manufacturing industry for medicines​” Gebre-Mariam said, adding that the approach will create jobs and promote skills development.

Local producers will also be better placed to meet specific local demand according to Gebre-Mariam, who said: “The disease burden in Ethiopia and other developing countries is not any more limited to communicable diseases; non-communicable diseases are on the rise.”

API manufacture

The Government's strategy will involve producing both active pharmaceutical ingredients (APIs) and finished dosage forms with efforts being tailored to meet the country’s needs.

Ethiopia is planning to produce medicines for neglected tropical diseases, which apparently are not the problem of the US and Europe​” Gebre-Mariam said.

He predicted that at least one local manufacturer would be making APIs by 2020 and suggested as many as four will be producing a limited number of drug actives by 2025.

Gebre-Mariam also expects – after sufficient production capacity and R&D infrastructure is established - that Ethiopian API and drug firms will supply other markets.

All market aspirations and success are based on market law- competitiveness… Ethiopia will explore the niche areas as it is endowed with huge potential​” he said, citing the country’s soil and plant flora as a diverse untapped resource for potential new medicines.

Related news

Show more

Related products

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more

Webinars